Krilogy Financial LLC Sells 306 Shares of Eli Lilly and Company (NYSE:LLY)

Krilogy Financial LLC trimmed its holdings in shares of Eli Lilly and Company (NYSE:LLYGet Rating) by 11.6% during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,331 shares of the company’s stock after selling 306 shares during the period. Krilogy Financial LLC’s holdings in Eli Lilly and were worth $756,000 as of its most recent filing with the SEC.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Orion Portfolio Solutions LLC boosted its holdings in shares of Eli Lilly and by 3.5% during the 2nd quarter. Orion Portfolio Solutions LLC now owns 5,570 shares of the company’s stock worth $1,806,000 after buying an additional 186 shares in the last quarter. Steigerwald Gordon & Koch Inc. lifted its holdings in shares of Eli Lilly and by 19.0% in the 2nd quarter. Steigerwald Gordon & Koch Inc. now owns 3,769 shares of the company’s stock worth $1,222,000 after purchasing an additional 603 shares in the last quarter. Adviser Investments LLC lifted its holdings in shares of Eli Lilly and by 12.2% in the 2nd quarter. Adviser Investments LLC now owns 1,465 shares of the company’s stock worth $475,000 after purchasing an additional 159 shares in the last quarter. Atalanta Sosnoff Capital LLC lifted its holdings in shares of Eli Lilly and by 49.8% in the 2nd quarter. Atalanta Sosnoff Capital LLC now owns 232,365 shares of the company’s stock worth $75,339,000 after purchasing an additional 77,298 shares in the last quarter. Finally, Highland Private Wealth Management lifted its holdings in shares of Eli Lilly and by 9.6% in the 2nd quarter. Highland Private Wealth Management now owns 1,812 shares of the company’s stock worth $587,000 after purchasing an additional 158 shares in the last quarter. 82.45% of the stock is currently owned by institutional investors.

Insider Transactions at Eli Lilly and

In other news, Director Jackson P. Tai purchased 656 shares of the business’s stock in a transaction dated Friday, August 12th. The stock was bought at an average price of $304.19 per share, for a total transaction of $199,548.64. Following the purchase, the director now owns 62,857 shares of the company’s stock, valued at $19,120,470.83. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. In other Eli Lilly and news, major shareholder Lilly Endowment Inc sold 1,601 shares of the firm’s stock in a transaction dated Tuesday, July 26th. The stock was sold at an average price of $332.52, for a total value of $532,364.52. Following the completion of the transaction, the insider now owns 103,964,899 shares in the company, valued at approximately $34,570,408,215.48. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Jackson P. Tai bought 656 shares of the business’s stock in a transaction on Friday, August 12th. The stock was bought at an average price of $304.19 per share, with a total value of $199,548.64. Following the purchase, the director now owns 62,857 shares in the company, valued at $19,120,470.83. The disclosure for this purchase can be found here. In the last 90 days, insiders sold 328,125 shares of company stock worth $108,581,151. 0.12% of the stock is owned by company insiders.

Eli Lilly and Trading Up 4.9 %

Shares of Eli Lilly and stock opened at $310.87 on Friday. Eli Lilly and Company has a 1 year low of $220.20 and a 1 year high of $335.33. The firm has a market cap of $295.38 billion, a PE ratio of 49.58, a P/E/G ratio of 1.92 and a beta of 0.38. The stock has a fifty day moving average price of $314.33 and a 200-day moving average price of $304.45. The company has a debt-to-equity ratio of 1.70, a current ratio of 1.10 and a quick ratio of 0.85.

Eli Lilly and (NYSE:LLYGet Rating) last announced its earnings results on Thursday, August 4th. The company reported $1.25 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.86 by ($0.61). Eli Lilly and had a net margin of 19.58% and a return on equity of 85.58%. The business had revenue of $6.49 billion for the quarter, compared to analysts’ expectations of $6.85 billion. During the same period in the prior year, the business earned $1.87 earnings per share. The company’s revenue for the quarter was down 3.7% compared to the same quarter last year. Equities research analysts anticipate that Eli Lilly and Company will post 7.97 EPS for the current year.

Eli Lilly and Dividend Announcement

The company also recently declared a quarterly dividend, which was paid on Friday, September 9th. Stockholders of record on Monday, August 15th were paid a dividend of $0.98 per share. The ex-dividend date was Friday, August 12th. This represents a $3.92 annualized dividend and a dividend yield of 1.26%. Eli Lilly and’s payout ratio is 62.52%.

Analysts Set New Price Targets

A number of equities analysts recently issued reports on the company. Morgan Stanley increased their target price on Eli Lilly and from $395.00 to $412.00 and gave the stock an “overweight” rating in a report on Wednesday, September 7th. Citigroup increased their target price on Eli Lilly and from $285.00 to $370.00 in a report on Thursday, August 25th. Barclays increased their price target on Eli Lilly and from $333.00 to $355.00 and gave the company an “overweight” rating in a research report on Thursday, July 7th. JPMorgan Chase & Co. increased their price target on Eli Lilly and from $340.00 to $355.00 in a research report on Wednesday, June 1st. Finally, BMO Capital Markets increased their price target on Eli Lilly and from $369.00 to $396.00 and gave the company an “outperform” rating in a research report on Tuesday, September 6th. Three equities research analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, Eli Lilly and presently has an average rating of “Moderate Buy” and a consensus target price of $332.19.

Eli Lilly and Company Profile

(Get Rating)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

See Also

Institutional Ownership by Quarter for Eli Lilly and (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and and related companies with MarketBeat.com's FREE daily email newsletter.